Adverse event totals15

The totals the trial posted for each group.

1 to 15 of 15

Total	Group	Affected	At risk
Total, all-cause mortality	Double-Blind 50mg	0	28
Total, all-cause mortality	Double-Blind 100mg/50mg	0	27
Total, all-cause mortality	Double-Blind Placebo	0	54
Total, all-cause mortality	Open-Label 50mg	0	93
Total, all-cause mortality	Follow-Up	0	80
Total, other adverse events	Double-Blind 50mg	4	28
Total, other adverse events	Double-Blind 100mg/50mg	3	27
Total, other adverse events	Double-Blind Placebo	2	54
Total, other adverse events	Open-Label 50mg	5	93
Total, other adverse events	Follow-Up	1	80
Total, serious adverse events	Double-Blind 50mg	2	28
Total, serious adverse events	Double-Blind 100mg/50mg	0	27
Total, serious adverse events	Double-Blind Placebo	1	54
Total, serious adverse events	Open-Label 50mg	3	93
Total, serious adverse events	Follow-Up	0	80

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01688037/event-totals